US/UK/Canada

Share

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -
Tags ( Active)

Information about Summons to the Annual General Meeting of Diamyd Medical AB

The following summons to the Annual General Meeting will be available at Diamyd Medical's website www.diamyd.com from Thursday November 8, 2012.Summons to the Annual General Meeting of Diamyd Medical ABThe shareholders of Diamyd Medical AB (publ) are hereby summoned to the Annual General Meeting on Thursday December 6, 2012 at 3.00 p.m. in Wenströmsalen, IVA Konferenscenter, at Grev Turegatan 16 in Stockholm, Sweden. AttendanceShareholders who wish to attend the meeting must be recorded in the register of shareholders held by Euroclear Sweden AB by Friday November 30, 2012, and must

Bulletin from Annual General Meeting: Diamyd Medical towards new goals

At Diamyd Medical’s Annual General Meeting on December 7, Peter Zerhouni, President and CEO, commented that the past year had been eventful and turbulent, but that the Company now stands well-equipped to continue its efforts to develop innovative pharmaceuticals for diseases for which there are currently no effective treatment options.The event that dominated the latter part of Diamyd Medical’s fiscal year was the results of the Company’s European Phase III study in type 1 diabetes with the drug candidate Diamyd®, which did not meet expectations. Since the results were presented in May 2011,

Information about Summons to the Annual General Meeting of Diamyd Medical AB

The follwing summons to the Annual General Meeting will be available at Diamyd Medical's website www.diamyd.com from Wednesday November 9, 2011.Summons to the Annual General Meeting of Diamyd Medical AB The shareholders of Diamyd Medical AB (publ) are hereby summoned to the Annual General Meeting on Wednesday December 7, 2011 at 3.00 p.m. in Stora Hörsalen, Garnisonen, at Karlavägen 100 in Stockholm, Sweden. AttendanceShareholders who wish to attend the meeting must be recorded in the register of shareholders held by Euroclear Sweden AB by Thursday December 1, 2011, and must also

Bulletin from Annual General Meeting: One of the most significant years in Diamyd’s history

At Diamyd Medical’s Annual General Meeting on December 9, Elisabeth Lindner, President and CEO of Diamyd, said that the past year was one of the most significant years in the history of the company and that the foundation has been laid upon which a new Swedish pharmaceutical company can be built.“I am very pleased that we continued to deliver according to plan in the past year,” says Elisabeth Lindner, President and CEO of Diamyd Medical. “Following an eventful year, we will now continue to develop Diamyd into a new Swedish pharmaceutical company.” In addition to the signing of a

Diamyd Medical publishes the Annual Report for 2009/2010

Diamyd Medical's Annual Report for 2009/2010 is from today available in Swedish on the company website, www.diamyd.com.The printed version of the Annual Report can be ordered from Diamyd Medical by mail: Diamyd Medical, Karlavägen 108, SE-115 26 Stockholm, or by e-mail to investor.relations@diamyd.com.  Diamyd Medical's Annual General Meeting takes place on Thursday December 9, 2010 at 3:00 p.m. at the IVA Conference Center, Grev Turegatan 16 (Wallenberg auditorium) in Stockholm.  The English translation of the Annual Report will be available in approximately two weeks.

Diamyd Medical executes a 2:1 division of shares (a split)

Diamyd Medical announces today that the company executes a 2:1 division of shares (i.e. a split), meaning that each share is divided into two shares of the same class.At Diamyd´s Annual General Meeting on December 11, 2009, it was decided to perform a division of shares in the ratio 2:1. Authorized by the Annual General Meeting, the Board has determined the dates for the execution of the division as follows. Record day for the division is Thursday January 28, 2010. The last day of trading in the Diamyd share before the division is Monday January 25, 2010. The first day of trading with

Bulletin from shareholders' meeting: Diamyd stands stronger than ever

At Diamyd Medical’s ordinary Annual General Meeting on December 11, CEO Elisabeth Lindner announced that Diamyd stands stronger than ever before. The first of the company’s Phase III studies of the Diamyd® diabetes vaccine is fully recruited and the recruitment of the other Phase III study is steadily increasing. Additionally, several children have been vaccinated in a Swedish prevention study of the Diamyd® diabetes vaccine with the aim of preventing type 1 diabetes.“It has been an incredibly exciting and intense year for Diamyd where a number of important events have contributed to our

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media